Baird Have Price Target $20 on Natera (NASDAQ:NTRA). Analysts Maintain firms “Outperform” rating.

June 29, 2018 - By Arnold Ferreira

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

Baird have a $20 PT on Natera (NASDAQ:NTRA) shares. On 28 June the $1.05 billion MC company have “Outperform” stock rating. This PT gives a potential 4.22 % upside on the stock.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

A total of 4 analysts rate Natera (NASDAQ:NTRA) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:NTRA) has 8 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Wednesday, March 14 the rating was maintained by Canaccord Genuity with “Buy”. On Monday, June 25 Canaccord Genuity maintained Natera, Inc. (NASDAQ:NTRA) rating. Canaccord Genuity has “Buy” rating and $20 target. On Wednesday, March 14 the company was maintained by Robert W. Baird. On Friday, June 22 Craig Hallum maintained the shares of NTRA in report with “Buy” rating. On Wednesday, May 9 the firm has “Overweight” rating given by Morgan Stanley. On Monday, June 25 Morgan Stanley maintained Natera, Inc. (NASDAQ:NTRA) with “Overweight” rating. On Thursday, June 28 the stock of Natera, Inc. (NASDAQ:NTRA) has “Outperform” rating given by Robert W. Baird.

NTRA is touching $19.19 during the last trading session, after increased 1.16%.Natera, Inc. has volume of 209,466 shares. Since June 29, 2017 NTRA has risen 12.60% and is uptrending. NTRA outperformed the S&P500 by 0.03%.

On August, 14 WallStreet awaited Natera, Inc. (NASDAQ:NTRA)’s earnings report, according to Zacks. Last year’s earnings per share was $-0.52, while now analysts expect change of 1.92 % down from current $-0.53 earnings per share. Analysts at Wall Street see Natera, Inc.’s -13.11 % EPS growth compared to $-0.61 earnings per share for previous quarter.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The company has $1.05 billion market cap. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Last it reported negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news released briefly go to: Seekingalpha.com, Benzinga.com, Streetinsider.com, Benzinga.com or Benzinga.com. The titles are as follows: “Key events next week – healthcare” released on June 21, 2018, “40 Stocks Moving In Wednesday’s Mid-Day Session” on June 27, 2018, “Natera (NTRA) Announces Powerful Kidney Transplant Rejection Biomarker” with a publish date: June 21, 2018, “44 Biggest Movers From Yesterday” and the last “42 Biggest Movers From Yesterday” with publication date: June 28, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: